Literature DB >> 23975241

Visual loss and perimetric sensitivity in eyes with retinitis pigmentosa.

Hiroyuki Iijima1.   

Abstract

PURPOSE: To investigate the various perimetric parameters that best predict reduction of best-corrected visual acuity (BCVA) to worse than 0.5 in the near future in eyes with retinitis pigmentosa (RP).
METHODS: The most recent records obtained by Humphrey Field Analyzer (HFA) central 10-2 perimetry were studied for the right eyes of 123 patients (60 men and 63 women) with typical RP. The correlation between various parameters of perimetric sensitivity and BCVA was retrospectively studied. The receiver operating characteristic (ROC) curves were used to find the best parameter to discriminate eyes with BCVA ≥0.5 from those with BCVA <0.5.
RESULTS: Spearman rank correlation coefficients with logMAR BCVA were the highest for the foveal threshold (FT) and mean sensitivity of the test points within 1.4° of the fixation point (MS1.4). The ROC curve analysis revealed that the area under the curve was the largest for the MS1.4 among all the perimetric parameters for discriminating eyes with BCVA ≥0.5 from those with BCVA <0.5. The cutoff value of 30 dB showed 100 % specificity and 57 % sensitivity.
CONCLUSIONS: The risk of vision decreasing below 0.5 in the near future may be predicted when the mean sensitivity within 1.4° of the fixation point in the HFA 10-2 reaches 30 dB in eyes with RP.

Entities:  

Mesh:

Year:  2013        PMID: 23975241     DOI: 10.1007/s10384-013-0271-7

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  9 in total

1.  Perceived and actual performance of daily tasks: relationship to visual function tests in individuals with retinitis pigmentosa.

Authors:  J P Szlyk; W Seiple; G A Fishman; K R Alexander; S Grover; C L Mahler
Journal:  Ophthalmology       Date:  2001-01       Impact factor: 12.079

2.  Progression of defects in the central 10-degree visual field of patients with retinitis pigmentosa and choroideremia.

Authors:  H Hirakawa; H Iijima; T Gohdo; M Imai; S Tsukahara
Journal:  Am J Ophthalmol       Date:  1999-04       Impact factor: 5.258

3.  Correlation between visual sensitivity loss and years affected for eyes with retinitis pigmentosa.

Authors:  Hiroyuki Iijima
Journal:  Jpn J Ophthalmol       Date:  2012-04-03       Impact factor: 2.447

4.  Relationship between difficulty in performing daily activities and clinical measures of visual function in patients with retinitis pigmentosa.

Authors:  J P Szlyk; G A Fishman; K R Alexander; B I Revelins; D J Derlacki; R J Anderson
Journal:  Arch Ophthalmol       Date:  1997-01

5.  Clinical trial of lutein in patients with retinitis pigmentosa receiving vitamin A.

Authors:  Eliot L Berson; Bernard Rosner; Michael A Sandberg; Carol Weigel-DiFranco; Robert J Brockhurst; K C Hayes; Elizabeth J Johnson; Ellen J Anderson; Chris A Johnson; Alexander R Gaudio; Walter C Willett; Ernst J Schaefer
Journal:  Arch Ophthalmol       Date:  2010-04

6.  Visual acuity and 10 degrees automated static perimetry in eyes with retinitis pigmentosa.

Authors:  Keitetsu Abe; Hiroyuki Iijima; Hirohide Hirakawa; Yasushi Tsukahara; Yoshiki Toda
Journal:  Jpn J Ophthalmol       Date:  2002 Sep-Oct       Impact factor: 2.447

7.  Effect of nilvadipine on central visual field in retinitis pigmentosa: a 30-month clinical trial.

Authors:  Mitsuru Nakazawa; Hiroshi Ohguro; Kimio Takeuchi; Yasuhiro Miyagawa; Tadashi Ito; Tomomi Metoki
Journal:  Ophthalmologica       Date:  2010-10-16       Impact factor: 3.250

8.  Long-term survival of central visual field in end-stage glaucoma.

Authors:  Jason W Much; Chengcheng Liu; Jody R Piltz-Seymour
Journal:  Ophthalmology       Date:  2007-12-11       Impact factor: 12.079

9.  Clinical trial of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin A treatment.

Authors:  Eliot L Berson; Bernard Rosner; Michael A Sandberg; Carol Weigel-DiFranco; Ann Moser; Robert J Brockhurst; K C Hayes; Chris A Johnson; Ellen J Anderson; Alexander R Gaudio; Walter C Willett; Ernst J Schaefer
Journal:  Arch Ophthalmol       Date:  2004-09
  9 in total
  6 in total

1.  Development and validation of a visual field cluster in retinitis pigmentosa.

Authors:  Takashi Omoto; Akio Oishi; Ryo Asaoka; Yuri Fujino; Hiroshi Murata; Keiko Azuma; Manabu Miyata; Ryo Obata; Tatsuya Inoue
Journal:  Sci Rep       Date:  2021-05-06       Impact factor: 4.379

2.  Longitudinal study of visual field changes determined by Humphrey Field Analyzer 10-2 in patients with Retinitis Pigmentosa.

Authors:  Akira Sayo; Shinji Ueno; Taro Kominami; Kazuki Nishida; Daiki Inooka; Ayami Nakanishi; Shunsuke Yasuda; Satoshi Okado; Kunihiko Takahashi; Shigeyuki Matsui; Hiroko Terasaki
Journal:  Sci Rep       Date:  2017-11-27       Impact factor: 4.379

3.  Assessment of Central Visual Function in Patients with Retinitis Pigmentosa.

Authors:  Kohta Fujiwara; Yasuhiro Ikeda; Yusuke Murakami; Takashi Tachibana; Jun Funatsu; Yoshito Koyanagi; Shunji Nakatake; Noriko Yoshida; Shintaro Nakao; Toshio Hisatomi; Shigeo Yoshida; Takeshi Yoshitomi; Tatsuro Ishibashi; Koh-Hei Sonoda
Journal:  Sci Rep       Date:  2018-05-23       Impact factor: 4.379

4.  Acupuncture for retinitis pigmentosa: study protocol for a randomised, sham-controlled trial.

Authors:  Hui Huang; Jing Wang; Haoran Li; Ruxue Lei; Weiwen Zou; Qun Huang; Na Gao; Yanlin Zheng
Journal:  BMJ Open       Date:  2021-11-12       Impact factor: 2.692

Review 5.  Progression Rate of Visual Function and Affecting Factors at Different Stages of Retinitis Pigmentosa.

Authors:  Nana Ito; Gen Miura; Yuki Shiko; Yohei Kawasaki; Takayuki Baba; Shuichi Yamamoto
Journal:  Biomed Res Int       Date:  2022-07-14       Impact factor: 3.246

6.  Aqueous Flare and Progression of Visual Field Loss in Patients With Retinitis Pigmentosa.

Authors:  Kohta Fujiwara; Yasuhiro Ikeda; Yusuke Murakami; Takashi Tachibana; Jun Funatsu; Yoshito Koyanagi; Shunji Nakatake; Shotaro Shimokawa; Noriko Yoshida; Shintaro Nakao; Toshio Hisatomi; Tatsuro Ishibashi; Koh-Hei Sonoda
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-07-01       Impact factor: 4.799

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.